Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Reaching cholesterol targets: Which medicine to use?
Reaching cholesterol targets: Which medicine to use?

Pharmacist prescriber Linda Bryant runs through the options available to a patient on statin therapy that has been ineffective at reducing his cardiovascular risk
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Ministry of Health. Cardiovascular Disease Risk Assessment and Management for Primary Care. Wellington, NZ: Ministry of Health; 2018.
2. Lee SJ, Joo JH, Park S, et al. Combination therapy with moderate-intensity atorvastatin and ezetimibe versus high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability. Eur Heart J Cardiovasc Pharmacother 2023; 10 November online.
3. Yu M, Liang C, Kong Q, et al. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis 2020;19(1):1.
4. Lee B, Hong SJ, Rha SW, et al. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial. Atherosclerosis 2023;386:117373.
5. Reddy V, Allison J, Mounsey A. Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD? J Fam Pract 2023;72(5):227–29.
6. Alrajeh K, AlAzzeh O, Roman Y. The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing. Pharmacogenomics 2023;24(7):381–98.
7. Lee YJ, Hong SJ, Kang WC, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ 2023;383:e075837.
8. Shin JI, Fine DM, Sang Y, et al. Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol 2022;33(9):1767–77.